Nuclear Medicine and Biology
Volume 36, Issue 7 , Pages 789-800 , October 2009

Bifunctional phage-based pretargeted imaging of human prostate carcinoma

  • Jessica R. Newton-Northup

      Affiliations

    • Department of Biochemistry, University of Missouri, Columbia, MO 65211, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 573 882 1493; fax: +1 573 884 4597.
    • ,
  • Said D. Figueroa

      Affiliations

    • Department of Radiology, University of Missouri, Columbia, MO 65211, USA
    • ,
  • Thomas P. Quinn

      Affiliations

    • Department of Biochemistry, University of Missouri, Columbia, MO 65211, USA
    • Research Service, Harry S. Truman Veterans Memorial Hospital, Columbia, MO 65201, USA
    • ,
  • Susan L. Deutscher

      Affiliations

    • Department of Biochemistry, University of Missouri, Columbia, MO 65211, USA
    • Research Service, Harry S. Truman Veterans Memorial Hospital, Columbia, MO 65201, USA

Received 27 February 2009 ,Revised 22 April 2009 ,Accepted 27 April 2009.

References 

  1. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453–2463
  2. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259–1266
  3. Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, et al. Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol. 2004;143:99–106
  4. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med. 2006;47:793–796
  5. Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276–2282
  6. Palm S, Back T, Claesson I, Danielsson A, Elgqvist J, Frost S, et al. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int J Radiat Oncol Biol Phys. 2007;69:572–579
  7. Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, et al. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res. 2008;14:875–882
  8. Song H, Shahverdi K, Huso DL, Esaias C, Fox J, Liedy A, et al. 213Bi (Alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res. 2008;68:3873–3880
  9. Mattes MJ, Goldenberg DM. Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electrons. Eur J Nucl Med Mol Imaging. 2008;35:1249–1258
  10. Reilly RM. Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens. J Nucl Med. 2006;47:196–199
  11. Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging. 2006;50:248–264
  12. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med. 2003;44:400–411
  13. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693–713
  14. Axworthy DB, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A. 2000;97:1802–1807
  15. Su FM, Beaumier P, Axworthy D, Atcher R, Fritzberg A. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator. Nucl Med Biol. 2005;32:741–747
  16. Wangler C, Moldenhauer G, Eisenhut M, Haberkorn U, Mier W. Antibody-dendrimer conjugates: the number, not the size of the dendrimers, determines the immunoreactivity. Bioconjug Chem. 2008;19:813–820
  17. Pan H, Han L, Chen W, Yao M, Lu W. Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes. J Control Release. 2008;125:228–235
  18. Nobs L, Buchegger F, Gurny R, Allemann E. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjug Chem. 2006;17:139–145
  19. Natarajan A, Xiong CY, Gruettner C, DeNardo GL, DeNardo SJ. Development of multivalent radioimmunonanoparticles for cancer imaging and therapy. Cancer Biother Radiopharm. 2008;23:82–91
  20. Forero-Torres A, Shen S, Breitz H, Sims RB, Axworthy DB, Khazaeli MB, et al. Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein. Cancer Biother Radiopharm. 2005;20:379–390
  21. Corneillie TM, Whetstone PA, Meares CF. Irreversibly binding anti-metal chelate antibodies: artificial receptors for pretargeting. J Inorg Biochem. 2006;100:882–890
  22. Barbet J, Kraeber-Bodere F, Chatal JF. What can be expected from nuclear medicine tomorrow?. Cancer Biother Radiopharm. 2008;23:483–504
  23. Newton JR, Miao Y, Deutscher SL, Quinn TP. Melanoma imaging with pretargeted bivalent bacteriophage. J Nucl Med. 2007;48:429–436
  24. Zou J, Dickerson MT, Owen NK, Landon LA, Deutscher SL. Biodistribution of filamentous phage peptide libraries in mice. Mol Biol Rep. 2004;31:121–129
  25. Ruoslahti E. Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol. 2000;10:435–442
  26. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12:697–715
  27. Newton JR, Kelly KA, Mahmood U, Weissleder R, Deutscher SL. In vivo selection of phage for the optical imaging PC-3 human prostate carcinoma in mice. Neoplasia. 2006;8:772–780
  28. Kelly KA, Waterman P, Weissleder R. In vivo imaging of molecularly targeted phage. Neoplasia. 2006;8:1011–1018
  29. Segers J, Laumonier C, Burtea C, Laurent S, Elst LV, Muller RN. From phage display to magnetophage, a new tool for magnetic resonance molecular imaging. Bioconjug Chem. 2007;18:1251–1258
  30. Rusckowski M, Gupta S, Liu G, Dou S, Hnatowich DJ. Investigations of a (99m)Tc-labeled bacteriophage as a potential infection-specific imaging agent. J Nucl Med. 2004;45:1201–1208
  31. Rusckowski M, Gupta S, Liu G, Dou S, Hnatowich DJ. Investigation of four (99m)Tc-labeled bacteriophages for infection-specific imaging. Nucl Med Biol. 2008;35:433–440
  32. Schechter B, Silberman R, Arnon R, Wilchek M. Tissue distribution of avidin and streptavidin injected to mice. Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin. Eur J Biochem. 1990;189:327–331
  33. Wilbur DS, Hamlin DK, Buhler KR, Pathare PM, Vessella RL, Stayton PS, et al. Streptavidin in antibody pretargeting: 2. Evaluation of methods for decreasing localization of streptavidin to kidney while retaining its tumor binding capacity. Bioconjug Chem. 1998;9:322–330
  34. Wilbur DS, Hamlin DK, Sanderson J, Lin Y. Streptavidin in antibody pretargeting: 4. Site-directed mutation provides evidence that both arginine and lysine residues are involved in kidney localization. Bioconjug Chem. 2004;15:1454–1463
  35. Smith GP. Lab homepage. http://www.biosci.missouri.edu/smithGP/University of Missouri-Columbia
  36. Jin X, Newton JR, Montgomery-Smith S, Smith G. A generalized kinetic model for amine modification of proteins with application to phage display. Biotechniques. 2009;46:175–182
  37. Smith GP. Kinetics of amine modification of proteins. Bioconjug Chem. 2006;17:501–506
  38. Silber HB, Ghajari N, Maraschin V. Eu(III) complexation constants with glutamine and serine in aqueous methanol. J Alloys Compd. 2000;112–115
  39. Savinainen KJ, Saramaki OR, Linja MJ, Bratt O, Tammela TL, Isola JJ, et al. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol. 2002;160:339–345
  40. Kumar SR, Quinn TP, Deutscher SL. Evaluation of an 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas. Clin Cancer Res. 2007;13:6070–6079
  41. Muller WA, Weigl SA, Deng X, Phillips DM. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med. 1993;178:449–460
  42. Newman PJ. The biology of PECAM-1. J Clin Invest. 1997;99:3–8
  43. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA. 2000;97:14608–14613
  44. di Tomaso E, Capen D, Haskell A, Hart J, Logie JJ, Jain RK, et al. Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res. 2005;65:5740–5749
  45. Merril CR, Scholl D, Adhya SL. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov. 2003;2:489–497
  46. Geier MR, Trigg ME, Merril CR. Fate of bacteriophage lambda in non-immune germ-free mice. Nature. 1973;246:221–223
  47. Inchley CJ, Howard JG. The immunogenicity of phagocytosed T4 bacteriophage: cell replacement studies with splenectomized and irradiated mice. Clin Exp Immunol. 1969;5:189–198
  48. Inchley CJ. The activity of mouse Kupffer cells following intravenous injection of T4 bacteriophage. Clin Exp Immunol. 1969;5:173–187
  49. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol. 2003;163:1801–1815
  50. Rosebrough SF. Pharmacokinetics and biodistribution of radiolabeled avidin, streptavidin and biotin. Nucl Med Biol. 1993;20:663–668
  51. Sabatino G, Chinol M, Paganelli G, Papi S, Chelli M, Leone G, et al. A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors. J Med Chem. 2003;46:3170–3173
  52. Hamblett KJ, Press OW, Meyer DL, Hamlin DK, Axworthy D, Wilbur DS, et al. Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma. Bioconjug Chem. 2005;16:131–138
  53. Forster GJ, Santos EB, Smith-Jones PM, Zanzonico P, Larson SM. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J Nucl Med. 2006;47:140–149
  54. Landon LA, Zou J, Deutscher SL. Is phage display technology on target for developing peptide-based cancer drugs?. Curr Drug Discov Technol. 2004;1:113–132
  55. Mori T. Cancer-specific ligands identified from screening of peptide-display libraries. Curr Pharm Des. 2004;10:2335–2343
  56. Kumar SR, Deutscher SL. 111In-Labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors. J Nucl Med. 2008;49:796–803
  57. Kelly KA, Jones DA. Isolation of a colon tumor specific binding peptide using phage display selection. Neoplasia. 2003;5:437–444
  58. Chen X, Sievers E, Hou Y, Park R, Tohme M, Bart R, et al. Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia. 2005;7:271–279
  59. Lovric J, Bazzi HS, Cuie Y, Fortin GR, Winnik FM, Maysinger D. Differences in subcellular distribution and toxicity of green and red emitting CdTe quantum dots. J Mol Med. 2005;83:377–385
  60. Shiohara A, Hoshino A, Hanaki K, Suzuki K, Yamamoto K. On the cyto-toxicity caused by quantum dots. Microbiol Immunol. 2004;48:669–675

☆ This work was supported by a Merit Review award from the Veterans Administration and by grant NIH P50 CA103130-01.

PII: S0969-8051(09)00124-3

doi: 10.1016/j.nucmedbio.2009.04.010

Nuclear Medicine and Biology
Volume 36, Issue 7 , Pages 789-800 , October 2009

Article Tools

* Image Usage & Resolution